دورية
18F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12)
| العنوان: | 18F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12) |
|---|---|
| المؤلفون: | Nakamura, Masato, Satake, Hironaga, Sagawa, Tamotsu, Takagane, Akinori, Sekikawa, Takashi, Oguchi, Kazuhiro, Kaji, Tomohito, Takeuchi, Masahiro, Ichikawa, Wataru, Fujii, Masashi |
| المصدر: | Oncology and Therapy; 20210101, Issue: Preprints p1-11, 11p |
| مستخلص: | Introduction: Regorafenib is a multikinase inhibitor approved for the treatment of metastatic colorectal cancer (mCRC). Despite providing a statistically significant survival benefit, a substantial number of patients fail to respond to or continue with treatment, which has resulted in an unmet clinical need for a biomarker of regorafenib efficacy. Methods: The JACCRO CC-12 study was a prospective, multicenter, single-arm phase II trial designed to evaluate the usefulness of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) as an imaging biomarker of regorafenib in patients with mCRC that progressed after standard chemotherapies. FDG-PET and contrast-enhanced computed tomography (CT) were performed before and after treatment with regorafenib 160 mg once daily 3 weeks on/1 week off. The primary end point was the change in the maximum standardized uptake value in the lesion with the highest uptake at pre-treatment FDG-PET. The secondary end points included overall survival (OS), progression-free survival (PFS), the objective response rate (ORR), safety, and the correlation between FDG-PET and CT. Results: Twenty patients were enrolled from November 2014 to March 2016, 17 of whom were evaluated for metabolic and morphological changes. Metabolic response with FDG-PET was partial response (PR) in one case (5.9%), stable disease (SD) in four (23.5%), and progressive disease (PD) in 12 (70.6%). The metabolic response rate was 5.9%. On CT imaging, no complete response or PR was observed, and the ORR was 0%. Median PFS and OS were 1.7 and 9.8 months, respectively. The median PFS of patients who achieved PR or SD by FDG-PET was 3.7 months, whereas that of those assessed as PD was 1 month (p= 0.13). The median OS of patients who achieved PR or SD by FDG-PET was 13.0 months, whereas that of patients assessed as PD was 10.6 months (p= 0.43). Frequent adverse events were palmar–plantar erythrodysesthesia syndrome, hypertension, loss of appetite, and fatigue. Conclusions: In this study, FDG-PET failed to demonstrate usefulness as an early imaging biomarker of regorafenib in patients with mCRC. |
| قاعدة البيانات: | Supplemental Index |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edo Supplemental Index ejs58010994 910 6 Periodical serialPeriodical 910.468933105469 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=ejs58010994&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edo&genre=article&issn=23661070&ISBN=&volume=&issue=Preprints&date=20210101&spage=1&pages=1-11&title=Oncology and Therapy&atitle=18F-FDG-PET%2FCT%20as%20an%20imaging%20biomarker%20for%20regorafenib%20efficacy%20in%20metastatic%20colorectal%20cancer%20%28JACCRO%20CC-12%29&id=DOI:10.1007/s40487-021-00173-1 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => 18F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12)
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Nakamura%2C+Masato%22">Nakamura, Masato</searchLink><br /><searchLink fieldCode="AR" term="%22Satake%2C+Hironaga%22">Satake, Hironaga</searchLink><br /><searchLink fieldCode="AR" term="%22Sagawa%2C+Tamotsu%22">Sagawa, Tamotsu</searchLink><br /><searchLink fieldCode="AR" term="%22Takagane%2C+Akinori%22">Takagane, Akinori</searchLink><br /><searchLink fieldCode="AR" term="%22Sekikawa%2C+Takashi%22">Sekikawa, Takashi</searchLink><br /><searchLink fieldCode="AR" term="%22Oguchi%2C+Kazuhiro%22">Oguchi, Kazuhiro</searchLink><br /><searchLink fieldCode="AR" term="%22Kaji%2C+Tomohito%22">Kaji, Tomohito</searchLink><br /><searchLink fieldCode="AR" term="%22Takeuchi%2C+Masahiro%22">Takeuchi, Masahiro</searchLink><br /><searchLink fieldCode="AR" term="%22Ichikawa%2C+Wataru%22">Ichikawa, Wataru</searchLink><br /><searchLink fieldCode="AR" term="%22Fujii%2C+Masashi%22">Fujii, Masashi</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Oncology and Therapy; 20210101, Issue: Preprints p1-11, 11p ) Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => Introduction: Regorafenib is a multikinase inhibitor approved for the treatment of metastatic colorectal cancer (mCRC). Despite providing a statistically significant survival benefit, a substantial number of patients fail to respond to or continue with treatment, which has resulted in an unmet clinical need for a biomarker of regorafenib efficacy. Methods: The JACCRO CC-12 study was a prospective, multicenter, single-arm phase II trial designed to evaluate the usefulness of [<superscript>18</superscript>F]fluorodeoxyglucose positron emission tomography (FDG-PET) as an imaging biomarker of regorafenib in patients with mCRC that progressed after standard chemotherapies. FDG-PET and contrast-enhanced computed tomography (CT) were performed before and after treatment with regorafenib 160 mg once daily 3 weeks on/1 week off. The primary end point was the change in the maximum standardized uptake value in the lesion with the highest uptake at pre-treatment FDG-PET. The secondary end points included overall survival (OS), progression-free survival (PFS), the objective response rate (ORR), safety, and the correlation between FDG-PET and CT. Results: Twenty patients were enrolled from November 2014 to March 2016, 17 of whom were evaluated for metabolic and morphological changes. Metabolic response with FDG-PET was partial response (PR) in one case (5.9%), stable disease (SD) in four (23.5%), and progressive disease (PD) in 12 (70.6%). The metabolic response rate was 5.9%. On CT imaging, no complete response or PR was observed, and the ORR was 0%. Median PFS and OS were 1.7 and 9.8 months, respectively. The median PFS of patients who achieved PR or SD by FDG-PET was 3.7 months, whereas that of those assessed as PD was 1 month (p= 0.13). The median OS of patients who achieved PR or SD by FDG-PET was 13.0 months, whereas that of patients assessed as PD was 10.6 months (p= 0.43). Frequent adverse events were palmar–plantar erythrodysesthesia syndrome, hypertension, loss of appetite, and fatigue. Conclusions: In this study, FDG-PET failed to demonstrate usefulness as an early imaging biomarker of regorafenib in patients with mCRC. ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1007/s40487-021-00173-1
)
)
[Languages] => Array
(
[0] => Array
(
[Code] => eng
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 11
[StartPage] => 1
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => 18F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12)
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Nakamura, Masato
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Satake, Hironaga
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Sagawa, Tamotsu
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Takagane, Akinori
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Sekikawa, Takashi
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Oguchi, Kazuhiro
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kaji, Tomohito
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Takeuchi, Masahiro
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ichikawa, Wataru
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Fujii, Masashi
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Text] => 20210101
[Type] => published
[Y] => 2021
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 23661070
)
[1] => Array
(
[Type] => issn-print
[Value] => 23661089
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => issue
[Value] => Preprints
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Oncology and Therapy
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |